Business Description
Zomedica Corp
NAICS : 339110
SIC : 3912
ISIN : CA98979F1071
Share Class Description:
ZOMDF: Ordinary SharesTotal Employee Number:
141Description
Zomedica Corp is a veterinary health company creating products for companion animals (canine, feline and equine) by focusing on the unmet needs of clinical veterinarians. The company's product portfolio includes diagnostics and therapeutics that emphasize patient health and practice health. The company is focused on the final development and commercialization of its TRUFORMA platform, which detects thyroid disorders in dogs & cats and adrenal disorders in dogs. Its segments consist of Diagnostics, Therapeutic Devices, and Development Services. It earns the majority of revenue from the therapeutics segment, which consists of Assisi, PulseVet, and VETIGEL products.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 23.62 | |||||
Equity-to-Asset | 0.91 | |||||
Debt-to-Equity | 0.02 | |||||
Debt-to-EBITDA | -0.12 | |||||
Interest Coverage | N/A |
N/A
|
N/A
| |||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | 1.98 | |||||
Beneish M-Score | -1.73 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 20.2 | |||||
3-Year EBITDA Growth Rate | -9.5 | |||||
3-Year EPS without NRI Growth Rate | -10.6 | |||||
3-Year FCF Growth Rate | -13.5 | |||||
3-Year Book Growth Rate | -24.4 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 58.72 | |||||
9-Day RSI | 53.17 | |||||
14-Day RSI | 50.09 | |||||
3-1 Month Momentum % | -18.11 | |||||
6-1 Month Momentum % | -3.53 | |||||
12-1 Month Momentum % | 154.9 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 7.01 | |||||
Quick Ratio | 6.33 | |||||
Cash Ratio | 5.55 | |||||
Days Inventory | 176.44 | |||||
Days Sales Outstanding | 30.73 | |||||
Days Payable | 62.64 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Shareholder Yield % | -0.05 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 66.29 | |||||
Operating Margin % | -71.97 | |||||
Net Margin % | -65.78 | |||||
EBITDA Margin % | -49.75 | |||||
FCF Margin % | -50.44 | |||||
OCF Margin % | -47.36 | |||||
ROE % | -18.7 | |||||
ROA % | -17.14 | |||||
ROIC % | -33.46 | |||||
3-Year ROIIC % | 10.54 | |||||
ROC (Joel Greenblatt) % | -93.71 | |||||
ROCE % | -20.02 | |||||
Moat Score | 2 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 2.73 | |||||
PB Ratio | 0.85 | |||||
Price-to-Tangible-Book | 1.37 | |||||
EV-to-EBIT | -1.95 | |||||
EV-to-EBITDA | -2.83 | |||||
EV-to-Revenue | 1.41 | |||||
EV-to-Forward-Revenue | 1.13 | |||||
EV-to-FCF | -2.79 | |||||
Price-to-GF-Value | 0.5 | |||||
| Price-to-Net-Current-Asset-Value | 1.91 | |||||
| Price-to-Net-Cash | 2.39 | |||||
Earnings Yield (Greenblatt) % | -51.28 | |||||
FCF Yield % | -18.47 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:ZOMDF
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return %
Total Annual Return %
Zomedica Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 34.329 | ||
| EPS (TTM) ($) | -0.02 | ||
| Beta | 1.1185 | ||
| 3-Year Sharpe Ratio | -0.02 | ||
| 3-Year Sortino Ratio | -0.03 | ||
| Volatility % | 103.71 | ||
| 14-Day RSI | 50.09 | ||
| 14-Day ATR ($) | 0.011319 | ||
| 20-Day SMA ($) | 0.094411 | ||
| 12-1 Month Momentum % | 154.9 | ||
| 52-Week Range ($) | 0.035 - 0.158 | ||
| Shares Outstanding (Mil) | 979.95 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Zomedica Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Zomedica Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-20 16:00 | In 145 days | ||
| Third quarter earnings results for 2026 | 2026-11-04 | In 128 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-21 16:00 | In 54 days | ||
| Second quarter earnings results for 2026 | 2026-08-06 | In 38 days | ||
| General meeting for 2026 | 2026-06-10 11:00 | 0.09 (+3.28%) | ||
| First quarter earnings conference call for 2026 | 2026-05-29 16:00 | 0.10 (+2.90%) | ||
| First quarter earnings results for 2026 | 2026-05-06 | 0.10 (+3.94%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-27 16:00 | 0.13 (+3.42%) | ||
| Annual report for 2025 | 2026-03-16 | 0.13 (-1.79%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-16 | 0.13 (-1.79%) |
Show
Entries
Zomedica Corp Frequently Asked Questions
What is Zomedica Corp(ZOMDF)'s stock price today?
The current price of ZOMDF is $0.10. The 52 week high of ZOMDF is $0.16 and 52 week low is $0.04.
When is next earnings date of Zomedica Corp(ZOMDF)?
The next earnings date of Zomedica Corp(ZOMDF) is 2026-08-06 Est..
Does Zomedica Corp(ZOMDF) pay dividends? If so, how much?
Zomedica Corp(ZOMDF) does not pay dividend.
Guru Commentaries on OTCPK:ZOMDF
No articles.
Press Release
Articles on Zomedica Corp
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers